Blog Tool

Sensydia Announces American Medical Association Category III CPT® Code for Noninvasive AI Hemodynamic Assessment. Groundbreaking code will facilitate use, adoption, and pathway for reimbursement of noninvasive AI hemodynamic assessment, including Sensydia’s Cardiac Performance System (CPS™). The new CPT code, 1036T, was published December 30, 2025, and will be effective July 1, 2026.

The NIH has activated Phase II funding of Sensydia’s Fast-Track STTR grant to support real-world clinical utility studies of the Cardiac Performance System (CPS™). This non-dilutive funding marks a key milestone as the company continues to validate CPS for patients with heart failure and pulmonary hypertension.

Industry veteran brings over 20 years of medical device leadership to guide operations, quality, and infrastructure as Sensydia advances toward FDA submission and commercialization of the Cardiac Performance System (CPS™).

Sensydia has enrolled the first patient in its pivotal clinical study evaluating the Cardiac Performance System (CPS™), a non-invasive solution for hemodynamic assessment. This milestone advances CPS™ toward FDA submission and supports Sensydia’s mission to transform the management of heart failure and other cardiac conditions through faster, safer diagnostics.

Completion of this 50-subject study is a key milestone on the path to delivering the first device for non-invasive and accurate...

Completion of this 50-subject study is a key milestone on the path to delivering the first device for non-invasive and accurate...

NIH STTR Fast-Track grant helps propel Sensydia's non-invasive CPS platform building on recent funding round Los Angeles, CA – June 5,...

Sensydia continues to push the boundaries of AI in heart function assessment Los Angeles, CA – May 9, 2023 – Non-invasive cardiac...

Completion of enrollment for this 225-subject study is a key milestone on the path to delivering the first device for non-invasive and...

External device uses heart sound and AI to deliver rapid cardiac function assessments via tablet to expand hemodynamic evaluation beyond...

Los Angeles – October 1, 2019 – Sensydia Corporation, an innovator in rapid, non-invasive measurement of critical cardiac function,...

The Sensydia Cardiac Performance System (CPS) is the first patient-worn system to provide Ejection Fraction information to clinicians for...

Sensydia Corporation announces that it has complete a Series B financing. The financing was led by Colle Capital and included all Series...

Sensydia Corporation has completed its first round of financing which will be used to develop its patent pending technology to detect...